Recursion Pharmaceuticals (RXRX) added ~11% in the morning trading on Wednesday after J.P. Morgan upgraded the AI-driven biotech to Overweight from Neutral, citing a blockbuster sales potential for ...

Abstract: The rapid expansion of cloud computing underscores the critical need for advanced security measures to protect sensitive data on remote servers. Authentication is crucial for safeguarding ...

The 8(a) small business contracting program is in a fight for its life. From Capitol Hill to the courts to now the executive branch, the 47-year-old program is facing questions about its legitimacy ...

The South Florida Water Management District's Python Elimination Program awards cash prizes to python removal agents. Kevin Pavlidis was the top winner for November, earning $2,500 for removing the ...

Before market open, Recursion divulged that its REC-4881 demonstrated notable efficacy in a phase 1b/2 trial. The drug, which treats a disorder called familial adenomatous polyposis (FAP) in which ...

The clinical-stage biotech might have a successful drug on its hands, if a relatively early-stage clinical trial is any indication. Its REC-4881 did very well in the testing. 10 stocks we like better ...

If only they were robotic! Instead, chatbots have developed a distinctive — and grating — voice. Credit...Illustration by Giacomo Gambineri Supported by By Sam Kriss In the quiet hum of our digital ...